Novo Nordisk has entered into a collaboration and license agreement with the Swiss company EraCal Therapeutics.
The two companies will develop and commercialize EraCal’s oral, small molecule program. The asset is believed to target a novel mechanism of action controlling appetite and body weight to treat obesity.
Milestones of up to EUR 235 million
Novo Nordisk obtains the exclusive rights to develop and commercialize the program under the agreement, while EraCal is eligible to receive upfront, development, and commercial milestones of up to EUR 235 million and further royalties on sales of a marketed product.
EraCal Therapeutics brings a unique drug discovery approach for obesity and other metabolic diseases.”
“EraCal Therapeutics brings a unique drug discovery approach for obesity and other metabolic diseases,” says Bei Zhang, CVP and therapeutic area head of diabetes, obesity, and MASH at Novo Nordisk. “We look forward to working with the EraCal team to realize the value of their platform and discover innovative medicines for people living with obesity.”
“This is an important agreement for EraCal Therapeutics as it showcases the team’s capabilities to identify new mechanisms of action and to discover and develop small molecules to target these biological pathways,” says Josua Jordi, CEO of EraCal Therapeutics. “We consider Novo Nordisk the ideal partner to bring this program to patients and are excited to join forces to lead innovation.”
Photo of Obesity R&D at Novo Nordisk A/S, Måløv, Denmark
